Drug intelligence / Profile preview

ketofol

Development stage: Phase 4
Modality: Small Molecules
Administration: Intravenous

Overview

Ketofol is a combination medication consisting of ketamine and propofol mixed together, typically in a 1:1 ratio. It is used for procedural sedation and analgesia, balancing the properties of both components. Ketofol functions through ketamine's NMDA receptor antagonism, providing analgesia, amnesia, and preserving respiratory drive, and propofol's GABA agonism, providing rapid sedation. The combination aims to counterbalance the adverse effects of each drug, such as propofol's hypotension and ketamine's psychomimetic effects.

Brand names: Ketofol
Other names: ketofol

Targets

NMDAR (Glutamate receptor ionotropic, NMDA)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on ketofol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ketofol.

Explore the full profile